http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 21 Jun 2026 20:00:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html <p>Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated TriadicMM-1, evaluating its tri-specific antibody IBI3003 for the treatment of relapsed or refractory multiple myeloma (R/R MM).</p> <p>The trial (NCT07623798) is a multicenter, randomized, controlled, open-label study comparing IBI3003 against an investigator's choice of either pomalidomide, bortezomib and dexamethasone, or daratumumab, pomalidomide and dexamethasone. The primary endpoint is progression-free survival assessed by an independent review committee. The trial targets patients in the second- to fifth-line treatment setting.</p> <p>IBI3003 targets three antigens — GPRC5D, BCMA, and CD3 — and is built on Innovent's http://www.streetinsider.com/FDA/Innovent+begins+Phase+3+trial+of+tri-specific+antibody+for+myeloma/26668818.html Sun, 21 Jun 2026 20:00:23 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/Press+Releases/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/PRNewswire/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/PRNewswire/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>June 21, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is http://www.streetinsider.com/PRNewswire/Innovent+Biologics+Announces+First+Patient+Dosed+in+a+Phase+3+Clinical+Trial+of+IBI3003%28GPRC5DBCMACD3+Tri-specific+Antibody%29+for+the+Treatment+of+Multiple+Myeloma/26668817.html Sun, 21 Jun 2026 20:00:00 -0400 01801 1801 6IB A.06822034 A.19420966 A.32437804 IVBIY O.00162576 O.04892715 O.20026344 O.39140405